All In Biotech

Drug Trial Radar · NCT02694523

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Last checked: Nov 20, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 684 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

684

Actual

Start

Mar 2016

Primary completion

Aug 2017

Study completion Aug 2017

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Boehringer Ingelheim
First posted
Feb 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Conditions

  • Psoriasis

Interventions

  • risankizumabDrug

    Risankizumab administered by subcutaneous (SC) injection

  • adalimumabBiological

    Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

  • placebo for risankizumabDrug

    Placebo risankizumab administered by subcutaneous (SC) injection

  • placebo for adalimumabBiological

    Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)Time frame: Week 16
  2. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)Time frame: Week 16
  3. Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)Time frame: Week 44

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.